# Iridex Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results
Ticker: IRIX
Company: IRIDEX
Source: IRIDEX
Published: 2026-06-25 13:46 EST
Original Source URL: https://iridex.gcs-web.com
## Summary

2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today

## Article Body
2026 Guidance Affirmed MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today
## Recent Company News
- 2026-06-25 13:46 EST — [Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference](https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-planet-microcap-las-vegas-2026-conference) — Source: IRIDEX
- 2026-06-25 13:46 EST — [Iridex Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-first-quarter-2026-financial-results) — Source: IRIDEX
- 2026-06-25 13:46 EST — [Iridex Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/IRIX/iridex-reports-third-quarter-2025-financial-results) — Source: IRIDEX
- 2026-06-25 13:46 EST — [Iridex to Present at the Sidoti Year-End Virtual Investor Conference](https://biopharmsignal.com/news/IRIX/iridex-to-present-at-the-sidoti-year-end-virtual-investor-conference) — Source: IRIDEX
- 2026-06-25 13:46 EST — [Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment](https://biopharmsignal.com/news/IRIX/iridex-announces-new-thermal-dynamics-study-that-strengthens-clinical-foundation-and-market-potential-of-micropulser-technology-and-continuous-wave-laser-for-glaucoma-treatment) — Source: IRIDEX
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)